definiens: within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, includi ng the statements pertaining to future plans to use the acquired franchise to be come the brand outlet for [COMPANY] 's pipeline of pain management products, f uture product improvements and line extensions, plans to expand the Company 's sales force and efforts, and collaborative work among the Company 's business uni ts to leverage the capabilities of the other business units to improve NeoSan 's products, including Darvon(R ) and Darvocet N(R ) products upon closing o f the transaction . These statements involve risks and uncertainties that cou ld cause actual results to differ materially, including, without limitation, r isks and uncertainties pertaining to [COMPANY] 's or its individual busines s units ' ability to successfully find, acquire, develop, improve, enhan ce the safety or efficacy of and sell, on a commercially profitable basis, pharm aceutical products without adversely affecting its fee - for - service client rela tionships or business opportunities . Additional factors that may cause th e actual results to differ materially are discussed in [COMPANY] 's recent fili ngs with the Securities and Exchange Commission, including, but not limited to, its registration statement, as amended, its Annual Report on Form 10 - K filed wi th the SEC on April 2, 2001, its Quarterly Reports on Form 10 - Q filed with the S EC on November 13, 2001, including the exhibits thereof, its Form 8 - Ks and i ts other periodic filings